middle.news
Argenica’s ARG-007 Shields Brain Cells from Injury in Major TBI Study
5:40pm on Sunday 1st of June, 2025 AEST
•
Biotechnology
Read Story
Argenica’s ARG-007 Shields Brain Cells from Injury in Major TBI Study
5:40pm on Sunday 1st of June, 2025 AEST
Key Points
ARG-007 reduces axonal injury biomarkers NF-H and APP to non-injured levels
Significant suppression of neuroinflammation marker Iba1 observed post-TBI
ARG-007 prevents acute plasma NF-L elevation, a key human TBI biomarker
Treated animals show improved motor function and faster weight recovery
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Argenica Therapeutics (ASX:AGN)
OPEN ARTICLE